ClinicalTrials.gg
CompletedNCT00603473Updated Feb 3, 2021Results posted

A Phase III Open-Label Study Of Gabapentin As Adjunctive Therapy In Japanese Pediatric Patients With Partial Seizures

A Phase 3 interventional study of gabapentin in Epilepsies, Partial, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 26 sites in Japan. Open to participants aged 3 Years to 15 Years. Per ClinicalTrials.gov, last updated 2021-02-03.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
92
Allocation
Non-randomized
Ages
3 Years to 15 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies in Epilepsies, Partial by Viatris Inc. — none open to participants now, none under way, none of them phase 3. Epilepsies, Partial · Viatris Inc..

Enrollment
9th of 13
92 · median 136
Started
2008
with 3 others
Phase 3
8 of 15
none open now
Registered
11th of 15
by date

Among the 15 studies in Epilepsies, Partial by Viatris Inc., this one is the 9th largest by enrollment of the 13 interventional ones that give a count, is one of 4 that started in 2008, is one of 8 in phase 3, and was the 11th registered.

Epilepsies, Partial

243 studies on the registry are indexed under Epilepsies, Partial; 49 are open to participants now.

Browse Epilepsies, Partial studies →

Open to participants now

None of the 15 studies in Epilepsies, Partial by Viatris Inc. is open now. The open studies under Epilepsies, Partial, anywhere →

Who these studies take

Of the 37 Epilepsies, Partial studies recruiting now, 9 (24%) set no upper age limit and 24 (65%) stop at 75 or younger; 17 take children under 18; 3 take healthy volunteers.

This study: 3 Years to 15 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 15 studies in Epilepsies, Partial by Viatris Inc. as a file.
02

Study summary

Examine the efficacy, safety and pharmacokinetics of gabapentin as adjunctive therapy in Japanese pediatric patients with partial seizures

03

Conditions studied

  • Epilepsies, Partial

Browse trials for

04

Who can participate

Ages eligible
3 Years to 15 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Japanese male or females, ages 3-15 years old at acquisition of , 15 years old or less at the baseline visit
  • Seizures are classified as simple partial, complex partial or partial becoming secondarily generalized (defined according to the International League Against Epilepsy)
  • Have not been able to achieve adequate seizure control with antiepileptic drugs

Exclusion criteria

Exclusion Criteria:

  • Seizures related to drugs or acute medical illness
  • History of any serious medical or psychiatric disorder
  • Diagnosis or history of a structural CNS lesion or an encephalopathy shown to be progressive
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
92 participants (actual)

Study arms

  • Experimental
    gabapentin

    Drug: gabapentin

Interventions

06

What researchers measure

Primary outcomes

  1. Response Ratio of Gabapentin in Japanese Pediatric Patients With Partial Seizures

    The Response Ratio calculated by the following equation was assessed as the primary endpoint: R Ratio = (T-B) / (T+B) where T is seizure frequency per 28 days (i.e., the number of seizures per 28 days) calculated from the total number of seizures for the 12-week treatment period, and B is seizure frequency per 28 days (i.e., the number of seizures per 28 days) calculated from the total number of seizures for the 6-week baseline period.

    Time frame: 12 weeks

Secondary outcomes

  1. Responder Rate

    Responder Rate was defined as the percentage of subjects with a 50% or greater reduction in the seizure frequency per 28 days for the 12-week treatment period in comparison with the frequency per 28 days for the 6-week baseline period.

    Time frame: 12 weeks

  2. Percent Change in Seizure Frequency (PCH)

    PCH calculated by the following equation was assessed as secondary endpoint: PCH = 100 (T-B) / B where T is seizure frequency per 28 days (i.e., the number of seizures per 28 days) calculated from the total number of seizures for the 12-week treatment period, and B is seizure frequency per 28 days (i.e., the number of seizures per 28 days) calculated from the total number of seizures for the 6-week baseline period.

    Time frame: 12 weeks

07

Results

Posted Feb 21, 2011

Participant flow

Participants were screened at 27 centers in Japan.

Participant flow — Overall Study
MilestoneGabapentin
Started89
Completed80
Not completed9
Withdrew: Adverse event4
Withdrew: Lack of efficacy4
Withdrew: Protocol violation1

Outcome measures

PrimaryResponse Ratio of Gabapentin in Japanese Pediatric Patients With Partial Seizures

The Response Ratio calculated by the following equation was assessed as the primary endpoint: R Ratio = (T-B) / (T+B) where T is seizure frequency per 28 days (i.e., the number of seizures per 28 days) calculated from the total number of seizures for the 12-week treatment period, and B is seizure frequency per 28 days (i.e., the number of seizures per 28 days) calculated from the total number of seizures for the 6-week baseline period.

Time frame:
12 weeks
Reported as:
Mean · ratio
Response Ratio of Gabapentin in Japanese Pediatric Patients With Partial Seizures
ratioGabapentin
Response Ratio of Gabapentin in Japanese Pediatric Patients With Partial Seizures-0.158 (-0.221 to -0.096)
SecondaryResponder Rate

Responder Rate was defined as the percentage of subjects with a 50% or greater reduction in the seizure frequency per 28 days for the 12-week treatment period in comparison with the frequency per 28 days for the 6-week baseline period.

Time frame:
12 weeks
Reported as:
Mean · Percentage of Subjects
Responder Rate
Percentage of SubjectsGabapentin
Responder Rate19.8 (12.0 to 29.8)
SecondaryPercent Change in Seizure Frequency (PCH)

PCH calculated by the following equation was assessed as secondary endpoint: PCH = 100 (T-B) / B where T is seizure frequency per 28 days (i.e., the number of seizures per 28 days) calculated from the total number of seizures for the 12-week treatment period, and B is seizure frequency per 28 days (i.e., the number of seizures per 28 days) calculated from the total number of seizures for the 6-week baseline period.

Time frame:
12 weeks
Reported as:
Median · Percent Change
Percent Change in Seizure Frequency (PCH)
Percent ChangeGabapentin
Percent Change in Seizure Frequency (PCH)-24.4 (-100.0 to 192.9)

Adverse events

Collected over 12-week treatment period, and 1-week follow-up period. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Gabapentin—1/89 (1.1%)73/89 (82%)
Most frequent serious events
Most frequent serious events
EventGabapentin
PharyngitisInfections and infestations1/89
Most frequent other events
Showing 10 of 17
Most frequent other events
EventGabapentin
SomnolenceNervous system disorders35/89
NasopharyngitisInfections and infestations24/89
InfluenzaInfections and infestations9/89
FallInjury, poisoning and procedural complications7/89
DiarrhoeaGastrointestinal disorders6/89
PharyngitisInfections and infestations6/89
ContusionInjury, poisoning and procedural complications6/89
PyrexiaGeneral disorders5/89
RashSkin and subcutaneous tissue disorders5/89
Upper respiratory tract infectionInfections and infestations4/89

Baseline characteristics

Age, Customized
Age, Customized(Subjects)Gabapentin
>= 3 years and < 5 years11
>= 5 years and < 13 years63
>= 13 years and =< 15 years15
Sex: Female, Male
Sex: Female, Male(Participants)Gabapentin
Female40
Male49
08

Study locations

26 sites
  • Pfizer Investigational Site
    Obu-shi,Morioka-machi, Aichi, Japan
  • Pfizer Investigational Site
    Jonan-ku, Fukuoka, Japan
  • Pfizer Investigational Site
    Sapporo, Hokkaido, Japan
  • Pfizer Investigational Site
    Kobe, Hyogo, Japan
  • Pfizer Investigational Site
    Suma-Ku, Kobe, Hyogo, Japan
  • Pfizer Investigational Site
    Kanazawa, Ishikawa, Japan
  • Pfizer Investigational Site
    Zentsuuji, Kagawa, Japan
  • Pfizer Investigational Site
    Yokohama, Kanagawa Pref., Japan
  • Pfizer Investigational Site
    Sendai-shi, Miyagi-ken, Japan
  • Pfizer Investigational Site
    Showa-Ku, Nagoya, Japan
  • Pfizer Investigational Site
    Niigata-shi, Niigata, Japan
  • Pfizer Investigational Site
    Kurashiki-City, Okayama Pref., Japan
  • Pfizer Investigational Site
    Okayama-shi, Okayama, Japan
  • Pfizer Investigational Site
    Izumi-shi, Osaka, Japan
  • Pfizer Investigational Site
    Miyakojima-ku, Osaka, Japan
  • Pfizer Investigational Site
    Suita, Osaka, Japan
  • Pfizer Investigational Site
    Higashimatsuyama, Saitama, Japan
  • Pfizer Investigational Site
    Shizuoka-shi, Shizuoka, Japan
  • Pfizer Investigational Site
    Kiyose-shi, Tokyo, Japan
  • Pfizer Investigational Site
    Kodaira, Tokyo, Japan
  • Pfizer Investigational Site
    Setagaya-ku, Tokyo, Japan
  • Pfizer Investigational Site
    Shinjuku-ku, Tokyo, Japan
  • Pfizer Investigational Site
    Hiroshima, Japan
  • Pfizer Investigational Site
    Saitama, Japan
  • Pfizer Investigational Site
    Yamagata, Japan
  • Pfizer Investigational Site
    Yamanashi, Japan
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2008, a primary completion of Dec 2009 and a completion of Dec 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2011, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 16, 2008
First posted
Jan 29, 2008
Start
Jan 2008
Primary completionActual
Dec 2009
CompletionActual
Dec 2009
Results first posted
Feb 21, 2011
Last update
Feb 3, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 3, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00603473
Responsible party
Sponsor
First posted
Jan 29, 2008
Start date
Jan 2008
Primary completion
Dec 2009
Completion
Dec 2009
Results posted
Feb 21, 2011
Last update
Feb 3, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gabapentin

Start the discussion